Proteosome inhibitors: A targeted therapy

V. D. Deepti, Hasitha Diana Manohar, K. Meena kumari, Navin Patil

Research output: Contribution to journalArticle

Abstract

Proteasome inhibition is a valid anticancer strategy. The ubiquitin proteasome pathway plays acritical role in regulating many processes in the cell which are important for tumour cell growth and survival. The proteosomal degradation is a highly complex and regulated process and is essential for cellular regulatory mechanism and maintaining homeostasis. In the ubiquitin proteasome pathway, the ubiquitin tagged proteins are recognised by 19s proteasomes and it is untagged by the same. The resultant protein substrates are unfolded by the enzyme ATPases; the substrates are fed into inner catalytic compartment of 20s proteasomes followed by the opening of molecular gate channel. These unfolded proteins are then hydrolyzed by 6 active proteolytic sites like Chymotrypsin like (CT-L), Caspase like (C-L) and trypsin like(T-L)on β-subunits into small polypeptides. This activity of proteasomes is inhibited by the proteasome inhibitors. Development of Proteosome inhibitors shows the hope for the cancer patients. This review facilitates easy understanding of the concepts of proteasome inhibitors, dealing in brief about the ubiquitin proteasome pathway, Biological effects of Pi,Therapeutic applications andto enlighten the approved drugs for clinical practice.

Original languageEnglish
Pages (from-to)488-497
Number of pages10
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number5
Publication statusPublished - 01-09-2016

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Protein Unfolding
Proteasome Inhibitors
Therapeutics
Proteins
Chymotrypsin
Cell growth
Therapeutic Uses
Substrates
Caspases
Trypsin
Adenosine Triphosphatases
Tumors
Catalytic Domain
Neoplasms
Cell Survival
Homeostasis
Degradation
Peptides

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{0f6549b47e054e24951da3fc5cfd6c97,
title = "Proteosome inhibitors: A targeted therapy",
abstract = "Proteasome inhibition is a valid anticancer strategy. The ubiquitin proteasome pathway plays acritical role in regulating many processes in the cell which are important for tumour cell growth and survival. The proteosomal degradation is a highly complex and regulated process and is essential for cellular regulatory mechanism and maintaining homeostasis. In the ubiquitin proteasome pathway, the ubiquitin tagged proteins are recognised by 19s proteasomes and it is untagged by the same. The resultant protein substrates are unfolded by the enzyme ATPases; the substrates are fed into inner catalytic compartment of 20s proteasomes followed by the opening of molecular gate channel. These unfolded proteins are then hydrolyzed by 6 active proteolytic sites like Chymotrypsin like (CT-L), Caspase like (C-L) and trypsin like(T-L)on β-subunits into small polypeptides. This activity of proteasomes is inhibited by the proteasome inhibitors. Development of Proteosome inhibitors shows the hope for the cancer patients. This review facilitates easy understanding of the concepts of proteasome inhibitors, dealing in brief about the ubiquitin proteasome pathway, Biological effects of Pi,Therapeutic applications andto enlighten the approved drugs for clinical practice.",
author = "Deepti, {V. D.} and Manohar, {Hasitha Diana} and {Meena kumari}, K. and Navin Patil",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "7",
pages = "488--497",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "5",

}

Proteosome inhibitors : A targeted therapy. / Deepti, V. D.; Manohar, Hasitha Diana; Meena kumari, K.; Patil, Navin.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 7, No. 5, 01.09.2016, p. 488-497.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proteosome inhibitors

T2 - A targeted therapy

AU - Deepti, V. D.

AU - Manohar, Hasitha Diana

AU - Meena kumari, K.

AU - Patil, Navin

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Proteasome inhibition is a valid anticancer strategy. The ubiquitin proteasome pathway plays acritical role in regulating many processes in the cell which are important for tumour cell growth and survival. The proteosomal degradation is a highly complex and regulated process and is essential for cellular regulatory mechanism and maintaining homeostasis. In the ubiquitin proteasome pathway, the ubiquitin tagged proteins are recognised by 19s proteasomes and it is untagged by the same. The resultant protein substrates are unfolded by the enzyme ATPases; the substrates are fed into inner catalytic compartment of 20s proteasomes followed by the opening of molecular gate channel. These unfolded proteins are then hydrolyzed by 6 active proteolytic sites like Chymotrypsin like (CT-L), Caspase like (C-L) and trypsin like(T-L)on β-subunits into small polypeptides. This activity of proteasomes is inhibited by the proteasome inhibitors. Development of Proteosome inhibitors shows the hope for the cancer patients. This review facilitates easy understanding of the concepts of proteasome inhibitors, dealing in brief about the ubiquitin proteasome pathway, Biological effects of Pi,Therapeutic applications andto enlighten the approved drugs for clinical practice.

AB - Proteasome inhibition is a valid anticancer strategy. The ubiquitin proteasome pathway plays acritical role in regulating many processes in the cell which are important for tumour cell growth and survival. The proteosomal degradation is a highly complex and regulated process and is essential for cellular regulatory mechanism and maintaining homeostasis. In the ubiquitin proteasome pathway, the ubiquitin tagged proteins are recognised by 19s proteasomes and it is untagged by the same. The resultant protein substrates are unfolded by the enzyme ATPases; the substrates are fed into inner catalytic compartment of 20s proteasomes followed by the opening of molecular gate channel. These unfolded proteins are then hydrolyzed by 6 active proteolytic sites like Chymotrypsin like (CT-L), Caspase like (C-L) and trypsin like(T-L)on β-subunits into small polypeptides. This activity of proteasomes is inhibited by the proteasome inhibitors. Development of Proteosome inhibitors shows the hope for the cancer patients. This review facilitates easy understanding of the concepts of proteasome inhibitors, dealing in brief about the ubiquitin proteasome pathway, Biological effects of Pi,Therapeutic applications andto enlighten the approved drugs for clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84987723189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987723189&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84987723189

VL - 7

SP - 488

EP - 497

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 5

ER -